Please assess the completion status of the following clinical trial:

Trial Title: Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent obtained prior to study procedures~* Histologically confirmed HCC with serum AFP \>200ng/ml at time of screening and following most current line of therapy OR radiographic diagnosis of HCC with serum AFP \>400ng/ml at time of screening and following most current line of therapy..~* Metastatic or locally advanced, unresectable HCC~* Must have failed or not tolerated, at least one line of systemic therapy for advanced HCC~* Molecular Human Leukocyte Antigen (HLA) class I allele typing confirms participant carries at least one HLA-A2 allele~* Life expectancy of at least 4 months~* Karnofsky Performance Scale greater than or equal to 70~* At least 1 measurable lesion on imaging by RECIST~* Child-Pugh A or B7~* Absolute neutrophil count greater than or equal to 1,500/mm\^3~* Platelet count greater than or equal to 30,000/mm\^3~Exclusion Criteria:~* Clinically significant cardiac disease~* Clinically significant pre-existing illness or active infection~* Clinically significant Central Nervous System (CNS) or neural dysfunction~* Active autoimmune disease requiring therapy~* Active malignancy other than HCC unless expected survival is greater than or equal to three years without any treatment (exception: hormone/androgen-depravation therapy) and without any organ involvement~* History of organ transplant~* Compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction~* Advanced HCC involving greater than one-third of the liver

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ET140202 T cells (Type: EXPERIMENTAL): ET140202 Receptor (+) T Cells

Based on this trial design, predict the completion outcome and termination type (if applicable).